Hepatocellular carcinoma (HCC), the major primary liver malignancy, is one of the leading causes of cancer-related deaths globally. Initiation and progression of HCC is considered a multi-step process. Genetics and epigenetics alterations contribute to the tumorigenesis of HCC, but the precise molecular events underlying HCC formation remain only partially understood. Recently, with the advancement of high-throughput biology techniques, bioinformatics analysis using integrated analytic approaches have been applied to multiple data platforms which contain large sets of clinically annotated HCC cases (eg. ATCC, GEPIA, UALCAN, TCGA, ONCOMINE, LinkedOmics, Kaplan-Meier Plotter, OncoLnc). Meanwhile, there has been an unprecedented expansion in the field of nanomedicine and immune-oncology with the development of new agents for the diagnosis and treatment of HCC. These valuable advances have given us a comprehensive and better understanding of HCC, and led to a number of clinical trials in HCC.
This Research Topic aims to make substantial advances in our knowledge of hepatocellular carcinoma by publishing outstanding research. We propagate work that leads to expand our knowledge in molecular mechanism, diagnosis, treatment, and prevention of hepatocellular carcinoma. Studies applying systems biology with integrated multi-omics studies are also welcome (see Note below). Article types to be considered are: Original Research, Review, Mini Review and Case Report.
This Research Topic will focus on the following topics on HCC:
- Molecular mechanism and/or biomarker research using technologies such as high-throughput sequencing, expression microarray, tissue microarray, proteomics, or metabonomics.
- Molecular mechanism and clinical transformation studies of immune-oncology.
- Nanooncology research: i) nanoparticles functioning as carriers for chemotherapeutic drugs or molecular targets to increase their therapeutic index; ii) nanoparticles functioning as therapeutic agents in photodynamic, gene, and thermal therapy; iii) nanoparticles used as molecular imaging agents to detect and monitor HCC progression.
- Clinical trials: monotherapy, combination treatment, or active substances of traditional Chinese medicine.
Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in this Research Topic.
Hepatocellular carcinoma (HCC), the major primary liver malignancy, is one of the leading causes of cancer-related deaths globally. Initiation and progression of HCC is considered a multi-step process. Genetics and epigenetics alterations contribute to the tumorigenesis of HCC, but the precise molecular events underlying HCC formation remain only partially understood. Recently, with the advancement of high-throughput biology techniques, bioinformatics analysis using integrated analytic approaches have been applied to multiple data platforms which contain large sets of clinically annotated HCC cases (eg. ATCC, GEPIA, UALCAN, TCGA, ONCOMINE, LinkedOmics, Kaplan-Meier Plotter, OncoLnc). Meanwhile, there has been an unprecedented expansion in the field of nanomedicine and immune-oncology with the development of new agents for the diagnosis and treatment of HCC. These valuable advances have given us a comprehensive and better understanding of HCC, and led to a number of clinical trials in HCC.
This Research Topic aims to make substantial advances in our knowledge of hepatocellular carcinoma by publishing outstanding research. We propagate work that leads to expand our knowledge in molecular mechanism, diagnosis, treatment, and prevention of hepatocellular carcinoma. Studies applying systems biology with integrated multi-omics studies are also welcome (see Note below). Article types to be considered are: Original Research, Review, Mini Review and Case Report.
This Research Topic will focus on the following topics on HCC:
- Molecular mechanism and/or biomarker research using technologies such as high-throughput sequencing, expression microarray, tissue microarray, proteomics, or metabonomics.
- Molecular mechanism and clinical transformation studies of immune-oncology.
- Nanooncology research: i) nanoparticles functioning as carriers for chemotherapeutic drugs or molecular targets to increase their therapeutic index; ii) nanoparticles functioning as therapeutic agents in photodynamic, gene, and thermal therapy; iii) nanoparticles used as molecular imaging agents to detect and monitor HCC progression.
- Clinical trials: monotherapy, combination treatment, or active substances of traditional Chinese medicine.
Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in this Research Topic.
